Trogenix’s mission is to develop effective, safe genetic medicines that are curative against multiple types of cancer and longevity-related disorders.
Trogenix is building a next-generation gene therapy platform to address the key challenges of safety and specificity in oncology. Using proprietary synthetic super enhancers (SSEs), Trogenix precisely targets therapeutic payloads to diseased cells, minimising off-target effects and maximising efficacy.
A spinout from the University of Edinburgh in 2023, Trogenix aims to redefine targeted cancer treatments, with an initial application in brain cancer (glioblastoma).
